For full-year 2017, the company reported $152.9 million in revenues, up 31 percent over 2016.
The funding will help the Canadian cancer genomics firm expand distribution of its tumor tissue hotspot test, and development of its newer liquid biopsy assay.
The group now plans to run the 32-gene panel in clinical trials to demonstrate its utility and make the case for offering it within Canada's healthcare system.
The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January.
The company beat analyst estimates on both the top and bottom line and reported a 50 percent year over year growth in clinical testing volume in Q3.
The companies plan to develop Thermo's Oncomine Dx Target Test as a companion diagnostic for Blueprint's BLU-667 to identify RET fusions in NSCLC patients.
The company says Panorama is the only NIPT that can tell whether twins are identical or fraternal, which can impact the clinical management of a pregnancy.
Today's agreement, which covers the UK, follows distribution deals OncoDNA signed earlier this month covering Morocco and Belarus.
Diagnostics firm BioHisto Maroc will market and distribute the firm's tissue-based and liquid biopsy sequencing services to oncologists and their patients.
Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.